DrugPatentWatch Database Preview
Litigation Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
» See Plans and Pricing
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
| Docket | Start Trial | Date Filed | 2014-07-03 |
| Court | District Court, D. Delaware | Date Terminated | 2016-11-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Sue Lewis Robinson |
| Jury Demand | None | Referred To | Judge Sherry R. Fallon |
| Parties | APOTEX INC.; MERCK SHARP & DOHME CORP.; TEVA PHARMACEUTICALS USA INC. | ||
| Patents | 6,127,353 | ||
| Attorneys | Andrew E. Riley; Aviv Zalcenstein; Bindu Ann George Palapura; David Ellis Moore; David M. Hashmall; Frederick H. Rein; Ira J. Levy; Joseph B. Crystal; Joshua A. Whitehill; Joshua P. Davis; Lindsay M. Volpenhein; Lisa M. Thomas; Michael B. Cottler; Michelle J. Eber; Nicolas G. Barzoukas; Richard L. Horwitz | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc.
The small molecule drug covered by the patent cited in this case is Start Trial .
Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-07-03 | 1 | product, prior to expiration of U.S. Patent No. 6,127,353 (“the ’353 patent”). PARTIES 2. Merck is a New Jersey…ACTION l. This is an action for patent infringement arising under the patent laws of the United States of…which is claimed in the ’353 patent, before the expiration of the ’353 patent, On information and belief…expiration of the ’353 patent, Teva was aware of the existence of the ’353 patent and that the filing of…which is claimed in the ’353 patent, before the expiration of the ’353 patent. On information and belief | External link to document | |
| 2014-07-31 | 13 | previously held, after trial, that U.S. Patent No. 6,127,353 (“the ‘353 patent”; D.I. 1-1) was not infringed …mometasone furoate infringes the ‘353 patent, even though that patent is directed to mometasone furoate…for Infringement of the ‘353 Patent Based on its Anhydrous Mometasone…for Infringement of the ‘353 Patent Based on its Anhydrous Mometasone… Sheridan Has Already Considered the ‘353 Patent and the Issue of Infringement | External link to document | |
| 2015-09-03 | 132 | alleging infringement of U.S. Patent No. 6, 127,353 ("the '353 patent") ("New Jersey/…henceforth will be to Civ. No. 14-874. to work on patent infringement litigation "relating to the drug…Merck failed to prove infringement of the '353 patent and dismissed Merck's claims. (Id., ex. 7A)…July 2014, asserting infringement of the '353 patent. Merck instituted Civ. No. 15-250 against defendant…March 2015, asserting infringement of the '353 patent. Also in March 2015, Merck instituted a second | External link to document | |
| 2015-09-03 | 133 | disputed claim language of U.S. Patent No. 6,127,353 ("the '353 patent") shall be construed…quot;Mometasone furoate monohydrate." The patented invention "relates to the novel compound… 16 November 2016 1:14-cv-00874-SLR-SRF Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
